METHODS: Primary rat bladder cell culture was used to evaluate the effect of bAR agonist and mAchR antagonist on extracellular matrix (ECM) production, oxidative stress and EMT markers in hypoxic environment. In the animal study, we used the well-established partial pelvic ischemia rat model by ligation of the common iliac artery. Rats were divided into five groups, including control group, ischemic bladder (IB) group, bAR agonist treated IB group, mAchR non-selective antagonist treated IB group, and mAchR selective antagonist treated IB group. Bladders were later be retrieved for evaluation of oxidative stress, along with ECM deposition and EMT markers RESULTS: In cell line study, response to hypoxia of bladder mucosa cells would be modified by both bAR agonist and mAchR antagonist. Decreased HIF-1a was found in treated cells, even after hypoxia. However, cells would demonstrate prominent EMT with collagen deposition, especially when treated with bAR agonist. In animal study, total glutathione can be a good indicator of ischemic severity. Both bAR agonist and mAchR antagonist can help improve urodynamic parameters from IB. This correlates with EMT after ischemic change but not with collagen and TGF-b expression. Bladder remodeling seemed to be associated more with selective mAchR antagonist treatment. Pathological evidence of ECM deposition can also be found in immunohistochemical stain of bladder.
INTRODUCTION AND OBJECTIVES: Current understanding of brain activity responsible for micturition control has primarily come from functional magnetic resonance imaging (fMRI). While providing excellent spatial resolution, fMRI is limited by poor temporal resolution and has unclear correlation with neuronal activity. Electrophysiological recordings may provide a more direct understanding of brain control of micturition. In this pilot study, we examined if electrocorticography (ECoG) can detect changes in brain activity during voiding in humans.
METHODS: Electrocorticogram (EcoG) data was retrospectively analyzed from 4 subjects who underwent ECoG electrode implantation for epilepsy surgery evaluation. Their video monitoring data was reviewed to identify the onset of urination events. Next, ECoG data was segmented into 40 s windows, centered around the onset of each urination. The ECoG data across all electrodes was then bandpass filtered into d (0-4 Hz), q (4-8 Hz), a (8-13 Hz), b (13-25 Hz), low-g (25-50 Hz), and high-g (70-110 Hz). The power across all bands and all events was found by squaring the resulting signals. The signal power before the onset of urination was compared to the signal power after urination using a rank-sum test. The electrodes demonstrating significant change in the signal power were registered to the subject's brain MRI to identify which areas are potentially involved in micturition control.
RESULTS: A total of 37, 31, 21, and 31 urination events were identified for Subject 1-4, respectively. All subjects consistently demonstrated a statistically significant modulation in the ECoG d, b, and low-g band in the temporal lobe (anterior and peri-sylvian areas) and the frontal lobe (prefrontal areas).
CONCLUSIONS: The results demonstrate that ECoG can detect changes in brain activity during voiding. ECoG modulation in the frontal areas may represent control of the external sphincter, while activity in the anterior and perisylvian areas may represent activity associated with bladder interoception (originating from insular cortex). Detection of electrophysiological signal changes during the micturition cycle opens the possibility of developing brain-computer interface systems or neuromodulatory techniques to improve bladder function, and classifying voiding dysfunctions based on their electrophysiological correlates. Future studies will focus on obtaining ECoG during controlled micturition (urodynamics) and assessing the ability of noninvasive electroencephalography to detect changes in brain activity during the micturition cycle.
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MP38-05 NLRP3 INFLAMMASOME MEDIATED INFLAMMATION AND DENERVATION ARE CRITICAL PROCESSES IN THE DEVELOPMENT OF DIABETIC BLADDER DYSFUNCTION
Francis Hughes, Brian Inouye, Eloise Stanton, Chloe Yun, Huixia Jin, J. Purves*, Durham, NC INTRODUCTION AND OBJECTIVES: Diabetic Bladder Dysfunction (DBD) is one of the most common complications experienced by diabetic patients, with an incidence as high as 87%. The NLRP3 inflammasome is known to produce inflammation in the kidney, retina and heart during diabetes and has been implicated as a mediator of inflammation in several cystopathies, including bladder outlet obstruction and chemical cystitis. In this study, we investigate the activation of NLRP3 in cultured urothelium and in the bladders of diabetic mice and demonstrate its deleterious effects on bladder function and innervation.
METHODS: Primary mouse urothelial cells in culture were exposed to several diabetic metabolites for 24 h and caspase-1 activity assessed. For the in vivo studies, four groups of mice were used: 1) control mice, 2) control mice with a NLRP3 null genotype (NLRP3-/-), 3) diabetic mice (Akita) and 4) diabetic/NLRP3-/-mice. All groups were assessed at 15 weeks of age for inflammation by Evan's blue extravasation, urinary function by awake, restrained urodynamics and nerve density by the number of PGP9.5+ cells/mm2 in cross-section.
RESULTS: NLRP3 in the mouse bladder was localized to the urothelium and was activated in vitro by a variety of diabetes-associated metabolites including glucose, uric acid, AGEs, HMGB1 and ceramide. Significant inflammation and activation of NLRP3 in urothelia was present by week 15 in diabetic mice. As shown in Figure 1 , diabetic mice also had decreased void volume and increased frequency by urodynamics, two indicators of early stage DBD. Significant increase in postvoid residual volume suggests a progression from an overactive (early) to underactive (late) phenotype. Most importantly, these pathological changes were absent in the NLRP3-/-group. Bladder nerve density was decreased in the diabetic animals compared to control, but was preserved in the diabetic NLRP3-/-mice.
CONCLUSIONS: Activation of urothelial inflammasomes by diabetic metabolites is a critical process underlying DBD, functioning in part by triggering denervation.
